Literature DB >> 7535932

gp130 and c-Kit signalings synergize for ex vivo expansion of human primitive hemopoietic progenitor cells.

X Sui1, K Tsuji, R Tanaka, S Tajima, K Muraoka, Y Ebihara, K Ikebuchi, K Yasukawa, T Taga, T Kishimoto.   

Abstract

gp130, a signal-transducing receptor component of interleukin 6 (IL-6), associates with an IL-6 and IL-6 receptor (IL-6) complex and transduces signals. To examine the role of gp130 signaling in the expansion of human hemopoietic progenitor cells, we tested the effects of a recombinant soluble human IL-6 receptor (sIL-6R) and/or IL-6 in combination with other cytokines on purified human umbilical cord blood CD34+ cells, using methylcellulose clonal assay and suspension culture in the presence or absence of serum. A combination of sIL-6R and IL-6 (sIL-6R/IL-6), but not sIL-6R or IL-6 alone, was found to dramatically stimulate expansion of hemopoietic progenitor cells as well as CD34+ cells in the presence of stem cell factor. Significant generation of multipotential hemopoietic progenitors over a period of 3 weeks in suspension culture and efficient formation of colonies, especially multilineage and blast cell colonies, in methylcellulose assay supplemented with a combination of sIL-6R/IL-6 together with stem cell factor were observed in serum-containing and serum-free culture. Addition of anti-gp130 monoclonal antibodies or anti-IL-6R monoclonal antibodies to the above cultures dose-dependently inhibited the expansion of progenitor cells in suspension culture and also completely blocked the formation of multilineage colonies in methylcellulose culture. These findings demonstrated that the significant expansion of human primitive hemopoietic progenitors could be achieved with the gp130 and c-Kit signalings initiated by the sIL-6R/IL-6 complex in the presence of stem cell factor and suggested the possible application of this method for ex vivo expansion of CD34+ cells for bone marrow transplantation.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7535932      PMCID: PMC42318          DOI: 10.1073/pnas.92.7.2859

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  25 in total

Review 1.  Interleukin-6 and its receptor: a paradigm for cytokines.

Authors:  T Kishimoto; S Akira; T Taga
Journal:  Science       Date:  1992-10-23       Impact factor: 47.728

2.  Characterization of IL-6 receptor expression by monoclonal and polyclonal antibodies.

Authors:  Y Hirata; T Taga; M Hibi; N Nakano; T Hirano; T Kishimoto
Journal:  J Immunol       Date:  1989-11-01       Impact factor: 5.422

3.  Net increase of pluripotential hematopoietic precursors in suspension culture in response to IL-1 and IL-3.

Authors:  N N Iscove; A R Shaw; G Keller
Journal:  J Immunol       Date:  1989-04-01       Impact factor: 5.422

4.  Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130.

Authors:  T Taga; M Hibi; Y Hirata; K Yamasaki; K Yasukawa; T Matsuda; T Hirano; T Kishimoto
Journal:  Cell       Date:  1989-08-11       Impact factor: 41.582

5.  Ex vivo expansion of enriched peripheral blood CD34+ progenitor cells by stem cell factor, interleukin-1 beta (IL-1 beta), IL-6, IL-3, interferon-gamma, and erythropoietin.

Authors:  W Brugger; W Möcklin; S Heimfeld; R J Berenson; R Mertelsmann; L Kanz
Journal:  Blood       Date:  1993-05-15       Impact factor: 22.113

6.  Maintenance of the pluripotential phenotype of embryonic stem cells through direct activation of gp130 signalling pathways.

Authors:  K Yoshida; I Chambers; J Nichols; A Smith; M Saito; K Yasukawa; M Shoyab; T Taga; T Kishimoto
Journal:  Mech Dev       Date:  1994-02       Impact factor: 1.882

7.  Hemopoietic colony-forming cells in umbilical cord blood with extensive capability to generate mono- and multipotential hemopoietic progenitors.

Authors:  T Nakahata; M Ogawa
Journal:  J Clin Invest       Date:  1982-12       Impact factor: 14.808

8.  Interleukin 6 enhancement of interleukin 3-dependent proliferation of multipotential hemopoietic progenitors.

Authors:  K Ikebuchi; G G Wong; S C Clark; J N Ihle; Y Hirai; M Ogawa
Journal:  Proc Natl Acad Sci U S A       Date:  1987-12       Impact factor: 11.205

9.  IL-6-induced homodimerization of gp130 and associated activation of a tyrosine kinase.

Authors:  M Murakami; M Hibi; N Nakagawa; T Nakagawa; K Yasukawa; K Yamanishi; T Taga; T Kishimoto
Journal:  Science       Date:  1993-06-18       Impact factor: 47.728

10.  Synergism of BSF-2/interleukin 6 and interleukin 3 on development of multipotential hemopoietic progenitors in serum-free culture.

Authors:  K Koike; T Nakahata; M Takagi; T Kobayashi; A Ishiguro; K Tsuji; K Naganuma; A Okano; Y Akiyama; T Akabane
Journal:  J Exp Med       Date:  1988-09-01       Impact factor: 14.307

View more
  22 in total

1.  Expansion in vitro of transplantable human cord blood stem cells demonstrated using a quantitative assay of their lympho-myeloid repopulating activity in nonobese diabetic-scid/scid mice.

Authors:  E Conneally; J Cashman; A Petzer; C Eaves
Journal:  Proc Natl Acad Sci U S A       Date:  1997-09-02       Impact factor: 11.205

2.  Engineering human interleukin-6 to obtain variants with strongly enhanced bioactivity.

Authors:  C Toniatti; A Cabibbo; E Sporena; A L Salvati; M Cerretani; S Serafini; A Lahm; R Cortese; G Ciliberto
Journal:  EMBO J       Date:  1996-06-03       Impact factor: 11.598

3.  Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide.

Authors:  I Walev; P Vollmer; M Palmer; S Bhakdi; S Rose-John
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-23       Impact factor: 11.205

4.  Expansion of human NOD/SCID-repopulating cells by stem cell factor, Flk2/Flt3 ligand, thrombopoietin, IL-6, and soluble IL-6 receptor.

Authors:  T Ueda; K Tsuji; H Yoshino; Y Ebihara; H Yagasaki; H Hisakawa; T Mitsui; A Manabe; R Tanaka; K Kobayashi; M Ito; K Yasukawa; T Nakahata
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

5.  Erythroid progenitors differentiate and mature in response to endogenous erythropoietin.

Authors:  T Sato; T Maekawa; S Watanabe; K Tsuji; T Nakahata
Journal:  J Clin Invest       Date:  2000-07       Impact factor: 14.808

6.  Targeted disruption of gp130, a common signal transducer for the interleukin 6 family of cytokines, leads to myocardial and hematological disorders.

Authors:  K Yoshida; T Taga; M Saito; S Suematsu; A Kumanogoh; T Tanaka; H Fujiwara; M Hirata; T Yamagami; T Nakahata; T Hirabayashi; Y Yoneda; K Tanaka; W Z Wang; C Mori; K Shiota; N Yoshida; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1996-01-09       Impact factor: 11.205

Review 7.  Ex vivo expansion of human hematopoietic stem cells.

Authors:  T Nakahata
Journal:  Int J Hematol       Date:  2001-01       Impact factor: 2.490

8.  Tunica interna endothelial cell kinase expression and hematopoietic and angiogenic potentials in cord blood CD34+ cells.

Authors:  Mika Wada; Yasuhiro Ebihara; Feng Ma; Hiroshi Yagasaki; Mamoru Ito; Tsuneo Takahashi; Hideo Mugishima; Shigeru Takahashi; Kohichiro Tsuji
Journal:  Int J Hematol       Date:  2003-04       Impact factor: 2.490

9.  Hepatocellular hyperplasia, plasmacytoma formation, and extramedullary hematopoiesis in interleukin (IL)-6/soluble IL-6 receptor double-transgenic mice.

Authors:  P Schirmacher; M Peters; G Ciliberto; M Blessing; J Lotz; K H Meyer zum Büschenfelde; S Rose-John
Journal:  Am J Pathol       Date:  1998-08       Impact factor: 4.307

10.  STAT3- and STAT5-dependent pathways competitively regulate the pan-differentiation of CD34pos cells into tumor-competent dendritic cells.

Authors:  Peter A Cohen; Gary K Koski; Brian J Czerniecki; Kevin D Bunting; Xin-Yuan Fu; Zhengqi Wang; Wen-Jun Zhang; Charles S Carter; Mohamed Awad; Christopher A Distel; Hassan Nagem; Christopher C Paustian; Terrence D Johnson; John F Tisdale; Suyu Shu
Journal:  Blood       Date:  2008-06-24       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.